Editas Medicine (EDIT) director Andrew Hirsch awarded 51,700 stock options

Rhea-AI Filing Summary

Editas Medicine director Andrew Hirsch received a stock option grant as part of his compensation. The award covers 51,700 options to buy Editas Medicine common stock at an exercise price of $2.55 per share. The option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027, with an expiration date of June 16, 2036. Following this grant, Hirsch holds 51,700 stock options directly, and there were no open‑market stock purchases or sales reported in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hirsch Andrew

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	51,700	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 51,700 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 51,700 options Exercise price: $2.55 per share Underlying shares: 51,700 shares +3 more

6 metrics

Stock options granted 51,700 options Grant on June 17, 2026

Exercise price $2.55 per share Stock option strike price

Underlying shares 51,700 shares Common Stock underlying the options

Post-grant option holdings 51,700 options Total options following this transaction

Vesting date June 17, 2027 Options vest in full on this date

Expiration date June 16, 2036 Option term end date

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, Common Stock, vest in full

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vest in full financial

"scheduled to vest in full on June 17, 2027"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hirsch Andrew

(Last) (First) (Middle)

C/O EDITAS MEDICINE, INC.,

11 HURLEY ST.

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.55	06/17/2026		A		51,700		(1)	06/16/2036	Common Stock	51,700	$0	51,700	D

Explanation of Responses:

1. This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027.

Remarks:

	/s/ Andrew Hirsch	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Andrew Hirsch report in this Form 4 for Editas Medicine (EDIT)?

Andrew Hirsch reported receiving a grant of stock options for 51,700 shares of Editas Medicine common stock. The options are a compensation award, not an open-market trade, and give him the right to buy shares at a fixed exercise price.

How many Editas Medicine (EDIT) stock options were granted to Andrew Hirsch?

Andrew Hirsch was granted 51,700 stock options linked to Editas Medicine common stock. These options represent the right to purchase 51,700 shares at a preset exercise price, once the options vest according to the specified schedule.

What is the exercise price of Andrew Hirsch’s Editas Medicine (EDIT) stock options?

The exercise price for Andrew Hirsch’s stock option grant is $2.55 per share. This means he can buy Editas Medicine common stock at $2.55 per share once the options are vested and before they expire, regardless of the market price then.

When do Andrew Hirsch’s Editas Medicine (EDIT) stock options vest and expire?

The stock options granted to Andrew Hirsch are scheduled to vest in full on June 17, 2027. They have an expiration date of June 16, 2036, giving him several years after vesting to exercise the options before they lapse.

Did Andrew Hirsch buy or sell Editas Medicine (EDIT) shares in the market?

This Form 4 does not report any open-market purchases or sales of Editas Medicine shares by Andrew Hirsch. It only reports a compensation-related grant of stock options, classified as a grant, award, or other acquisition transaction.